• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

NSAID utilization patterns following market withdrawal of rofecoxib

News
Article

Cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely prescribed for patients with arthritis and other conditions because of their lower risk for gastrointestinal adverse events compared with nonselective NSAIDs 1,2

Cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely prescribed for patients with arthritis and other conditions because of their lower risk for gastrointestinal adverse events compared with nonselective NSAIDs.1,2

On September 30, 2004, the COX-2 inhibitor rofecoxib was withdrawn from the market after a clinical trial demonstrated an increased risk of cardiovascular events in patients receiving chronic therapy with the drug.3 At the time of withdrawal, little data were available regarding the cardiovascular safety of other COX-2-selective and nonselective NSAIDs.

OBJECTIVES

STUDY METHODS

The study methods included:

Design: retrospective analysis of electronic pharmacy claims from a large managed care organization in the United States.

Time frame: index date defined as September 30, 2004, with a 4-month pre-index period and a 4-month post-index period.

Patient identification: adult patients aged 18 years or older at index who were continuously enrolled during the pre-index and post-index periods and who had pharmacy claim(s) for a COX-2 inhibitor or nonselective NSAID totaling at least a 90-day supply during the pre-index period.

Cohorts: patients were stratified by index NSAID (defined by the last NSAID filled during the pre-index period) into 2 cohorts (COX-2 inhibitor or nonselective NSAID), and further substratified based on the presence of cardiovascular risk, which was defined by a prescription fill for a cardiovascular or diabetes medication.

Baseline measures: demographics; concomitant use of a gastrointestinal-protective agent during the pre-index period; presence of cardiovascular risk.

Follow-up period outcome measures: continuation rate; discontinuation rate; switch rate (classified as switched when the first filled NSAID during the post-index period differed from the index NSAID).

Statistical methods: continuous variables were compared using t-test; categorical variables were compared using chi-square test.

RESULTS

DISCUSSION

CONCLUSIONS

Editors' Note: This study was originally presented as a poster at the Academy of Managed Care Pharmacy (AMCP) 17th Annual Meeting & Showcase, April 20–23, 2005, in Denver, Colo.

Dr Morikawa is a managed care pharmacy resident at Prescription Solutions, Costa Mesa, Calif. He can be reached via email at information@rxsolutions.comMs Vanderplas is a statistician, Dr Chang is chief statistician, and Dr Lew is a researcher with Health Informatics and Outcomes Research at Prescription Solutions. Prescription Solutions is a leading provider of pharmacy and medical management services, managing the prescription drug benefits of commercial, Medicare, and government health plans, employers, and unions, nationwide.

REFERENCES

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med. 2000;343:1520–1528.

2. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284: 1247–1255.

3. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.